Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis
Last month
Sionna selects which cystic fibrosis drug it will study in a mid-stage test
Last month
Lilly makes a move for long-acting incretins in tech deal with Swedish biotech
Last month
Deals
BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma
Last month
Deals
At ASCO, cell therapies for deadly form of brain cancer make early strides
Last month
Cell/Gene Tx
Lyra’s stock soars on Phase 3 success for chronic rhinosinusitis treatment
Last month
Regeneron makes $80M obesity deal with Hansoh
Last month
Deals
China
Phase 3 or bust: Why Lilly won't run mid-stage cancer trials
Last month
Enhertu combo has the makings of a new standard in HER2-positive breast cancer
Last month
Pharma
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
Last month
Deals
Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program
Last month
Vera posts positive Phase 3 rare kidney disease data, but crowded market looms
Last month
Pharma
In race with Merus, Bicara makes the case for two-year survival data
Last month
AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain
Last month
As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them
Last month
Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug
Last month
Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway
Last month
Cell/Gene Tx
Enhertu extends life by three months for some stomach cancer patients, study finds
Last month
Pharma
Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer
Last month
Pharma
Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs
Last month
Summit’s disappointing survival readout raises stakes for full data
Last month
Q&A: Why former Sen. Kyrsten Sinema is backing a psychedelic medicine with potentially more upside, but more risk
Last month
People
Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients
Last month
Pharma
Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop
Last month
First page
Previous page
2
3
4
5
6
7
8
Next page
Last page